Friday, 6th April 2018

9.00 – 9.05 am
Welcome
Christoph Zwietsch, Head of the CCC

9.05 – 9.20 am
Welcome
Markus Müller, Rector of the MedUni Vienna

1. Tumor Immunology – From Pathomechanism to Therapy
9.20 – 10.50 am
Session I: The Innate Aspect
Chair: Michael Trauner and Joachim Widder, MedUni Vienna/Vienna General Hospital

Keynote Speaker
Macrophages as therapeutics: re-polarization therapy in colorectal cancer
Niels Halama, Heidelberg University Hospital

EGFR: a journey from basic research to translation
Maria Sibilia, MedUni Vienna/Vienna General Hospital

Interferon signaling and tumor immunology
Dagmar Stolzer-Sakaguchi, MedUni Vienna/Vienna General Hospital

The tumor suppressor PTEN in myeloid cells regulates tumor immune surveillance
Gernot Schabbauer, MedUni Vienna/Vienna General Hospital

Anti-SIRPA antibody immunotherapy enhances neutrophil and macrophage anti-tumor activity in a humanized mouse model
Distmar Herdler-Brandstetter, MedUni Vienna/Vienna General Hospital

Development of oncolytic influenza viruses
Johannes Längle, MedUni Vienna/Vienna General Hospital

10.50 – 11.20 am
Break

11.20 am – 1.05 pm
Session II: Novel Therapeutic Options and Developments
Chair: Ursula Wiedermann and Michael Gnant, MedUni Vienna/Vienna General Hospital

Keynote Speaker
Targeting immune checkpoints in cancer: Mechanistic insights
Frederick Arce-Vargas, University College London

Novel immunotherapy combinations
Christoph Höller, MedUni Vienna/Vienna General Hospital

CAR-T cells go clinic
Ulrich Jäger, MedUni Vienna/Vienna General Hospital

Keynote Speaker
Oncolytic viruses in human glioma
Adel Samson, University of Leeds

Development of oncolytic influenza viruses
Johannes Längle, MedUni Vienna/Vienna General Hospital

1.05 – 2.00 pm
Lunch

2.00 – 3.00 pm
CCC Keynote Lecture
Chair: Maria Sibilia and Matthias Preusser, MedUni Vienna/Vienna General Hospital

Cell signalling by receptor tyrosine kinases; from basic principles to cancer therapy
Joseph Schlessinger, Yale School of Medicine, New Haven

3.00 – 3.30 pm
Break

3.30 – 5.15 pm
Session III: Bio-Markers and Therapy
Chair: Renate Kaín and Walter Berger, MedUni Vienna/Vienna General Hospital

Keynote Speaker
The immune contexture and immunoscore in the era of cancer immunotherapy
Jerome Galon, Inserm, Paris

Single-cell sequencing for immunology
Christoph Bock, CaMM Vienna/MedUni Vienna

Computing and probing cancer immunity
Zddio Trajanovski, Medical University of Innsbruck

The immunogenicity of cell death
Rudolf Dehez, MedUni Vienna/Vienna General Hospital

Emerging biomarkers for immunotherapies of cancer
Anna Berghoff, MedUni Vienna/Vienna General Hospital

Immunotherapy: new hope for challenging RCC patient populations?
Manuela Schmidinger, MedUni Vienna/Vienna General Hospital

5.15 – 5.50 pm
Break

5.50 pm
Interactive poster-session with flying dinner & networking
Saturday, 7th April 2018

2. Precision Medicine and Biomarkers
9.00 – 10:45 am
Session I: Basic to Translational - Rational Concepts
Chair: Markus Zeitlinger and Shahrokh Shariat, MedUni Vienna/Vienna General Hospital

Keynote Speaker
Tissue-like culture systems and organoids for drug development
Lukas Huber, Medical University of Innsbruck

Resistance mechanisms to antiangiogenic therapy in cancer
Balazs Dome, MedUni Vienna/Vienna General Hospital

Transcription factors in development of prostate cancer and ALCL
Lukas Kenner, MedUni Vienna/Vienna General Hospital

Epigenetic biomarkers in cancer
Gerda Egger, MedUni Vienna/Vienna General Hospital

TERT promoter mutations as prognostic factors in brain tumors
Walter Berger, MedUni Vienna/Vienna General Hospital

Genetic changes in adnexal tumors
Thomas Wiesner, MedUni Vienna/Vienna General Hospital

10.45 – 11.15 am
Break

11.15 am – 12.00 pm
Session II: Novel Targets, Markers and Molecular Guided Therapy I
Chair: Christoph Zielinski and Heinz Kölbl, MedUni Vienna/Vienna General Hospital

Keynote Speaker
The interface between chemistry and biology: membrane transporters
Giulio Superti-Furga, CeMM, Vienna

Targeting multiple mechanisms of LSC resistance in Ph+ CML
Peter Valant, MedUni Vienna/Vienna General Hospital

The EXALT trial: A functional precision medicine approach to haematological malignancies
Philipp Stabler, MedUni Vienna/Vienna General Hospital

EXACT trial
Gerald Prager, MedUni Vienna/Vienna General Hospital

Evidence for a direct link between metabolomics, epigenetic remodeling, inflammation and outcome in cancer
Dietmar Pils, MedUni Vienna/Vienna General Hospital

Markers between liver regeneration and oncological outcome
Patrick Starlinger, MedUni Vienna/Vienna General Hospital

12.00 – 2.00 pm
Lunch

2.00 – 3.45 pm
Session III: Markers and Molecular Guided Therapy II
Chair: Andreas Weinhäusel and Christian Herold, MedUni Vienna/Vienna General Hospital

Keynote Speaker
Novel strategies for early detection, risk prediction and prevention
Martin Widrig, University College London

New diagnostic concepts for detection and molecular characterization of ovarian cancer and premalignant lesions
Robert Zeitlinger, MedUni Vienna/Vienna General Hospital

The impact of liquid biopsies on precision medicine
Michael Speicher, Medical University of Graz

Liquid biopsy in EGFR-mutated advanced NSCLC
Martin Filipits, MedUni Vienna/Vienna General Hospital

Contributions of clinical pathology to precision medicine
Philipp Hofer, MedUni Vienna/Vienna General Hospital

From targets to imaging
Alexander Haug, MedUni Vienna/Vienna General Hospital

3.50 – 4.00 pm
Wrap up and presentation of the CCC Poster Award*
Matthias Preusser & Michael Bergmann

Meeting Chairs
Michael Bergmann, Matthias Preusser, Maria Sibilia

Scientific Committee
Catharina Disseler, Walter Berger, Christoph Bock, Michael Gnant, Lukas Kenner, Christoph Zeitlinger

* €5000/€3000/€2000 dedicated to research funding

This event will be approved by the Austrian Medical Chamber with 14 DFP-Points.